TUSTIN, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc. (JPI), the Company engages in the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. AMDL today announced:
2007 Net Revenues. The Company generated net revenues of $15.0 million from product sales in Fiscal Year 2007 compared to revenues from product sales of $2.1 million in FY 2006, an increase of $12.9 million or 614 percent. JPI was not acquired until September 28, 2006, therefore full year financials are not comparable. Gross profits were approximately $8.1 million in 2007 compared to gross profits of $933,493 in 2006. The Company had weighted average common shares outstanding as of December 31, 2006 and 2007 of 7,117,893 and 11,718,586, respectively.
2007 Net Loss and Net Loss Per Share. For FY 2007 AMDL's comprehensive net loss was $1.26 million or ($0.20) per share compared to a comprehensive net loss of $5.9 million or ($0.82) per share in FY 2006.
4th Quarter 2007 Results. The Company generated net revenues of
approximately $5,363,000 from product sales in the fourth quarter of 2007.
This is a 161% increase from the same period in 2006 of approximately
$2,049,000. Gross profits increased 156% to approximately $2,646,000
compared to approximately $1,035,000 for the same period in 2006. The
Company generated income after foreign currency gain of $498,903 of
approximately $1,414,000 for the quarter ended December 31, 2007 compared
to a comprehensive
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved